Denosumab Biosimilar - Anti-RANKL mAb - Research Grade
Source
DrugBank DB06643
Species
Human
Expression system
Mammalian cells
Molecular weight
144kDa
Purity
>85%
Buffer
PBS pH7.5
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
Denosumab,Denosumab,RANKL,anti-RANKL
Reference
PX-TA1018
Note
For research use only. Not suitable for human use.
Isotype
IgG2Kappa
Description of Denosumab Biosimilar - Anti-RANKL mAb - Research Grade
General information about Denosumab
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides.This product is for research use only.
Denosumab Biosimilar – Anti-RANKL mAb – Research Grade binds to CD254 / RANKL / TNFSF11, N-Fc, recombinant protein in indirect ELISA Assay
Immobilized CD254 / RANKL / TNFSF11, N-Fc, recombinant protein (cat. No.PX-P5597) at 5µg/mL (100µL/well) can bind to Denosumab Biosimilar – Anti-RANKL mAb – Research Grade (cat. No.PX-TA1018) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Denosumab Biosimilar – Anti-RANKL mAb – Research Grade” Cancel reply
Related products
Antigen
CD254 / RANKL / TNFSF11, N-Fc, recombinant protein
Reviews
There are no reviews yet.